A retron-based genome editing system, originally developed for E. coli, has now been adapted successfully across 15 bacterial species, according to a study reported by Genetic Engineering News. This platform could serve as a versatile tool for editing diverse bacteria, including those important for studying infectious diseases and biotechnology.
The approach leverages retrons—bacterial genetic elements that produce single-stranded DNA—to enable precise edits without leaving behind plasmid DNA. This reduces off-target effects compared to traditional methods like CRISPR-Cas9, though specific efficacy rates were not disclosed in the report.
Timeline to broader adoption remains uncertain. The researchers demonstrated the system's functionality across multiple species but have not announced a regulatory pathway or commercial partnerships. Further validation in additional strains and environments would be needed before it can be widely deployed in clinical or industrial settings.
The study was conducted by an academic team, and no immediate stock impact is noted for any company. The platform's potential to streamline engineering of microbes for drug production or bioremediation could eventually attract commercial interest, though no current market projections were provided.
Patient or environmental access to applications derived from this tool likely remains years away. Experts quoted in the report emphasize the need for extensive safety testing before retron-based edits are used in live organisms outside the lab.